- Conditions
- Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, WHO Grade 3 Glioma
- Interventions
- Pharmacological Study, Selinexor
- Other · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1465–1488
of 7,461
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
- Interventions
- Cannabidiol Oral Solution [Epidiolex]
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 65 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 12
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Gainesville, Florida + 9 more
- Conditions
- Postoperative Pain
- Interventions
- Oxymorphone IR
- Drug
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Stanford, California • Aurora, Colorado + 8 more
- Conditions
- Mental Health, Hypertension, Diabetes
- Interventions
- Individual awareness and focused behavior change
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Kidney Transplant Rejection
- Interventions
- Prospera
- Diagnostic Test
- Lead sponsor
- Natera, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 45 more
- Conditions
- Asthma
- Interventions
- Depemokimab, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 16
- States / cities
- Little Rock, Arkansas • Newport Beach, California • Aurora, Colorado + 11 more
- Conditions
- Heart Failure, Pulmonary Disease, Chronic Obstructive, Emphysema, Pulmonary Fibrosis, Interstitial Lung Disease
- Interventions
- ADAPT Intervention
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Seattle, Washington
- Conditions
- Contraception, Tuberculosis
- Interventions
- Rifampin 600 MG
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
- Interventions
- Glembatumumab Vedotin, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 17 more
- Conditions
- Progressive Glioblastoma, Recurrent Glioblastoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Lomustine, Magnetic Resonance Imaging, Nivolumab, Relatlimab, Surgical Procedure
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 325
- States / cities
- Jonesboro, Arkansas • Auburn, California • Duarte, California + 252 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- t:slim X2 with Control-IQ Technology & Dexcom G6 CGM, t:slim X2 with Basal-IQ & Dexcom G6 CGM
- Device
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 7
- States / cities
- Santa Barbara, California • Stanford, California • Aurora, Colorado + 4 more
- Conditions
- HER2 Positive Breast Cancer
- Interventions
- tucatinib, capecitabine, trastuzumab, placebo
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 612 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 66 more
- Conditions
- Non-Clear Cell Renal Cell Carcinoma
- Interventions
- XL092, Nivolumab, Sunitinib Malate
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 10
- States / cities
- Duarte, California • Newport Beach, California • San Francisco, California + 6 more
- Conditions
- Urothelial Carcinoma
- Interventions
- Not listed
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Orange, California • Palo Alto, California + 8 more
- Conditions
- Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy, Dystrophinopathy, Dystrophinopathy Symptomatic Female Carrier
- Interventions
- Observational study with patients who may be treated with various disease-modifying therapies
- Other
- Lead sponsor
- The Duchenne Registry
- Other
- Eligibility
- Not listed
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2072
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Sacramento, California • Aurora, Colorado + 7 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS)
- Device
- Lead sponsor
- Bigfoot Biomedical Inc.
- Industry
- Eligibility
- 7 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 3
- States / cities
- Santa Barbara, California • Stanford, California • Aurora, Colorado
- Conditions
- Proximal Junctional Kyphosis, Spino-pelvic Alignment, Thoracolumbar Spinal Fusion
- Interventions
- Not listed
- Lead sponsor
- NuVasive
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Pittsburgh, Pennsylvania
- Conditions
- Postbariatric Hypoglycemia
- Interventions
- Mizagliflozin 5 mg, Mizagliflozin 10 mg, Placebo
- Drug
- Lead sponsor
- Vogenx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 11
- States / cities
- Chula Vista, California • Palo Alto, California • Aurora, Colorado + 8 more
- Conditions
- Mobile Applications, Cell Phone Use, Mental Health Issue, Acceptability of Health Care, Feasibility
- Interventions
- Cogito Companion
- Behavioral
- Lead sponsor
- VA Eastern Colorado Health Care System
- Federal
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
- Interventions
- Ataluren
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 7 Years to 15 Years · Male only
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 21
- States / cities
- Los Angeles, California • Sacramento, California • Stanford, California + 18 more
- Conditions
- HIV Infections
- Interventions
- Standard of Care (SOC) Oral ART, Oral RPV, Oral CAB, RPV-LA Loading Dose, CAB-LA Loading Dose, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-809, Placebo, VX-770
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pamrevlumab, Placebo
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Magnetic Resonance Imaging, Trametinib Dimethyl Sulfoxide, Uprosertib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more